* BIOMEDICAL DIAGNOSTICS *
1986 - IDF Marne-la-Vallée (near Paris) www.bmd-net.com Discovery, Diagnostics (also, Design, Devices) Key words: Auto-immune diseases, Allergy test monitor, Caris, Fidis, Luminex Mission: to develop, manufacture and market quality and innovative IVD products for the diagnostic market of auto-immune diseases, allergies and infectious diseases Clients: Pharmaceutical industry bmd@bmd-net.com Age: 26 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up | Managing Dir.-CEO: Finance (Michel) [Ms. EM Lyon, ex-Carmat, Flamel Technologies, Aventis] Tech.Dir.-CTO: Parussini (Ermis), Ms.Sc. molecular biology, ex-Biomérieux Sc.Dir.-CSO: Sales Dir.: Sallen (Eric), Abbott, Becton Dickinson, Saint Gobain, Kottermann, SEROA] Fin.Dir.-CFO: BusDev: Financers (Hist.): Truffle Venture (majority share), CDC Entreprise, AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | Turnover (M€) : 11.25 (2009), 12.22 (2008), 15.6 (2006) Total funding (M€) : n.a. Last funding (M€) : 3.0 Focus : Allergy Position : Trade Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2011 .01 | Nomination : Michel Finance as CEO (replacing Paul Magrez) | ORGN | [25 years] |
| 2010 .03 | Partnering distribution agreement from Assuragen (USA) to commercialize its Signature Oncology Products in France | MKTG | [24 years] |
| 2009 .12 | 4th round-financing : 3.0 M€ by Truffle Venture and AGF P.E. | RFIND | [23 years] |
| 2008 .10 | Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), OSEO Innovation, to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics | DEBT | [22 years] |
| 2007 .00 | Nomination : Paul Magrez, as CEO (replacing Patrick G. Poty) | ORGN | [20 years] |
| 2005 .07 | 3rd round-financing : 5.0 M€, led by Truffle Venture and CDC Entreprise, with AGF P.E., Siparex, Auriga Partners, Ventech, 123 Multinova | RFINC | [19 years] |
| 2004 .05 | Nomination : Patrick G. Poty, as CEO (Daniel Pierron on leave) | ORGN | [18 years] |
| 2003 .05 | 2nd round-financing : 9.4 M€, by undisclosed investors | RFINB | [17 years] |
| 2000 .05 | 1st round-financing : 4.6 M€, by undisclosed investors | RFINA | [14 years] |
| 1986 .00 | Company founded by 2 ex-Abbott managers | ORGF | [0 year] | Actualisation / Updating: 23-Sep-2011 |
|